The 2025–2026 flu season marks the first widespread availability of AstraZeneca’s FluMist for self-administration at home. Following FDA approval in late 2024, the nasal spray vaccine can now be ordered online and administered by the patient or a caregiver without a clinic visit. This "Direct-to-Consumer" vaccination model is designed to increase public access and improve immunization rates, particularly in under-served rural areas.

The technical challenge of this model lies in "Patient Education" and ensuring correct administration technique. Most new devices now include QR codes on the packaging that link to concise video tutorials. For an analysis of the "Cold Chain" logistics and the stability of live-attenuated influenza vaccines in a home-delivery environment, refer to the Nasal Spray Market research. This shift is anticipated to reduce the burden on primary care providers during peak respiratory virus seasons.